Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults
Thomas P. Lodise, J. Nicholas O’Donnell, Stephen J. Balevic, Xing Liu, Kenan Gu, Jomy George, Shruti M. Raja, Jeffrey T. Guptill, Smitha Zaharoff, Nyssa Schwager, Vance G. Fowler, Alison Wall, Katherine Wiegand, Henry F. Chambers, Antibacterial Resistance Leadership Group
Abstract
] and area under the concentration-time curve [AUC]) and ALT/AST elevations in the analysis of subjects in the II ATM/CZA-ATM cohorts. The findings suggest that administration of CZA-ATM reduces ATM clearance but does not exacerbate AST/ALT elevations relative to ATM alone. The results also indicate that CI ATM should be used with caution.
Topics & Concepts
Ceftazidime/avibactamAztreonamPharmacokineticsCeftazidimeAvibactamMedicinePharmacologyInternal medicineBiologyPseudomonas aeruginosaGeneticsBacteriaAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyDrug Transport and Resistance Mechanisms